Tagged with NIH

USA Having terminated dozens of HIV-related research grants, the Trump administration’s assault on the field continues. In a major blow to the decades-long search for a vaccine, the US federal government has pulled the plug on the HIV vaccine programme run by the US National Institute of Health (NIH) –the world’s…

Saudi Arabia Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact on health, societies, and economies is enormous. Moreover, over 90 percent of rare diseases have no known treatment, and rare disease patients often face delayed diagnoses and…

Saudi Arabia Saudi Arabia is rapidly shaping its future as a global research powerhouse, channelling unprecedented resources into translational research, clinical trials, and genomics. At the heart of this transformation is the Saudi NIH, driving 13 key research priorities and forging strategic global partnerships. Speaking at The Global Healthspan Summit (GHS 2025)…

Japan A summary of some of the biggest stories coming out of Japan’s pharma industry, including Teva’s divestment of joint venture Teva-Takeda; GE HealthCare’s takeover of Nihon Medi-Physics; Takeda’s blood cancer anemia drug licensing deal with Keros, and Astellas’ new cell therapy research site in Japan.   Pharma firm Teva to…

Saudi Arabia Established as one of the initiatives launched by the Ministry of Health within Saudi Arabia’s Vision 2030, the Saudi National Institute for Health (Saudi NIH) aims to strengthen the Kingdom’s biomedical research landscape, funding high impact research and enhancing alignment with regulatory bodies. CEO and former academic Prof Fars Alanazi…

Global 35 years after the specific mechanisms and structure of the human immunodeficiency virus were first identified, the world is still waiting for a vaccine against HIV. Several late-stage candidates have failed in this time, leading to most of the major pharma companies exiting HIV vaccine research. Some new early-stage approaches…

Belgium Belgium, one of Europe’s most important countries for biopharmaceutical production and R&D, assumed presidency of the Council of the European Union on the first of January. As part of its Presidency Programme, Belgium has highlighted health as one of its 14 focus areas, with the hope of strengthening the three…

Belgium Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities to develop, manufacture and sell medicines.   Despite representing only a mid-size marketplace from an in-country commercial perspective, the comparatively…

Belgium Thanks to its world-renowned networks of medical and academic institutions, the long-standing presence of Big Pharma, and a favourable regulatory environment, Belgium has a well-established tradition of excellence in clinical trials. Pharma industry leaders and Belgian government officials weigh in on the factors threatening the country’s position as a clinical…

Belgium Diane Kleinermans leads the reimbursement commission at Belgium’s medicines payer, the National Institute for Health and Disability Insurance (NIHDI). With Belgium currently undergoing a landmark reform of its reimbursement procedure, Kleinermans discusses the access picture in the country today, international HTA collaborations, and the delicate balance between maintaining the stability…

Belgium Speaking exclusively to PharmaBoardroom, Pedro Facon outlines the scope and aims of the new medicines roadmap that NIHDI has recently presented to the Belgian Ministry of Health following extensive stakeholder discussions in 2022. In a wide-ranging and in-depth conversation, Facon describes his hopes for tackling the growing number and length…

USA PJ Brooks PhD, program director in the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) in the USA, highlights the importance of going beyond one disease at a time in clinical trials, some of the roadblocks that still remain…